Illumina, Inc. (ILMN)
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illumina: Multiple Headwinds Point To Limited Upside In 2025
Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles, notably from China and competition from Roche's SBX technology. Q1 2025 results were in line, but updated guidance predicts a revenue decline of 1%-3%, due to China headwinds and uncertain U.S. research funding. Despite a $100 million cost reduction program and ongoing R&D investments, Illumina's stock appears overvalued by nearly 18% based on a DCF analysis.
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips
ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.
Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Blanchett - Interim Head of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Dave Westenberg - Piper Sandler Jack Meehan - Nephron Vijay Kumar - Evercore Tycho Peterson - Jefferies Conor McNamara - RBC Capital Markets Mike Ryskin - Bank of America Kyle Mikson - Canaccord Operator Good day ladies and gentlemen, and welcome to the First Quarter 2025 Illumina Earnings Conference Call. At this time, all participants are in a listen only mode.
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Illumina (ILMN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.09 per share a year ago.
Unveiling Illumina (ILMN) Q1 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Illumina (ILMN) Earnings Expected to Grow: Should You Buy?
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Illumina (ILMN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders
Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing market is expected to grow by 14.90%-21.65% CAGR in the following ten years.
